Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.

Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov AS, Broder CC, Dimitrov DS.

Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755 . Review. Erratum in: Expert Opin Biol Ther. 2009 Apr;9(4):533.

2.

Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.

Zhu Z, Prabakaran P, Chen W, Broder CC, Gong R, Dimitrov DS.

Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Epub 2013 Apr 11. Review.

PMID:
23575729
3.

Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Zhu Z, Dimitrov AS, Bossart KN, Crameri G, Bishop KA, Choudhry V, Mungall BA, Feng YR, Choudhary A, Zhang MY, Feng Y, Wang LF, Xiao X, Eaton BT, Broder CC, Dimitrov DS.

J Virol. 2006 Jan;80(2):891-9.

4.

Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.

Elshabrawy HA, Fan J, Haddad CS, Ratia K, Broder CC, Caffrey M, Prabhakar BS.

J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5.

5.

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.

Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng Y, Middleton D, Wang LF, Broder CC, Dimitrov DS.

J Infect Dis. 2008 Mar 15;197(6):846-53. doi: 10.1086/528801.

6.

Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.

Chen W, Streaker ED, Russ DE, Feng Y, Prabakaran P, Dimitrov DS.

Biochem Biophys Res Commun. 2012 Jan 27;417(4):1164-9. doi: 10.1016/j.bbrc.2011.12.089. Epub 2011 Dec 27.

7.

Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.

Ying T, Du L, Ju TW, Prabakaran P, Lau CC, Lu L, Liu Q, Wang L, Feng Y, Wang Y, Zheng BJ, Yuen KY, Jiang S, Dimitrov DS.

J Virol. 2014 Jul;88(14):7796-805. doi: 10.1128/JVI.00912-14. Epub 2014 Apr 30.

8.

Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R.

J Virol. 2008 Apr;82(7):3220-35. doi: 10.1128/JVI.02377-07. Epub 2008 Jan 16.

9.

Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential.

Coughlin MM, Prabhakar BS.

Rev Med Virol. 2012 Jan;22(1):2-17. doi: 10.1002/rmv.706. Epub 2011 Sep 8. Review.

10.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.

Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. Epub 2007 Jul 9.

11.

Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.

Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC.

J Virol. 2005 Jun;79(11):6690-702.

12.

Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.

Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, Buckland R, Wild TF, Horvat B.

Virology. 2009 May 10;387(2):459-65. doi: 10.1016/j.virol.2009.03.001. Epub 2009 Mar 28.

13.

Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.

ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, Cheung CY, Bakker AQ, Bogaards JA, van Deventer E, Preiser W, Doerr HW, Chow VT, de Kruif J, Peiris JS, Goudsmit J.

PLoS Med. 2006 Jul;3(7):e237.

14.

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.

van den Brink EN, Ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J.

J Virol. 2005 Feb;79(3):1635-44.

15.

Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.

Zhu Z, Dimitrov AS, Chakraborti S, Dimitrova D, Xiao X, Broder CC, Dimitrov DS.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66. Review.

PMID:
16441209
16.

Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody.

Xu K, Rockx B, Xie Y, DeBuysscher BL, Fusco DL, Zhu Z, Chan YP, Xu Y, Luu T, Cer RZ, Feldmann H, Mokashi V, Dimitrov DS, Bishop-Lilly KA, Broder CC, Nikolov DB.

PLoS Pathog. 2013;9(10):e1003684. doi: 10.1371/journal.ppat.1003684. Epub 2013 Oct 10.

17.

Establishment and characterization of monoclonal antibodies against SARS coronavirus.

Ohnishi K.

Methods Mol Biol. 2008;454:191-203. doi: 10.1007/978-1-59745-181-9_15.

PMID:
19057876
18.

Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems.

Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, Eaton BT, Wang LF.

J Virol Methods. 2007 Jun;142(1-2):29-40. Epub 2007 Feb 9.

PMID:
17292974
19.

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.

Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD Jr, Coccia JA, Graziano RF, Srinivasan M, Lowy I, Finberg RW, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan JL, Ambrosino DM.

J Infect Dis. 2005 Feb 15;191(4):507-14. Epub 2005 Jan 14.

20.

Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.

Tripp RA, Haynes LM, Moore D, Anderson B, Tamin A, Harcourt BH, Jones LP, Yilla M, Babcock GJ, Greenough T, Ambrosino DM, Alvarez R, Callaway J, Cavitt S, Kamrud K, Alterson H, Smith J, Harcourt JL, Miao C, Razdan R, Comer JA, Rollin PE, Ksiazek TG, Sanchez A, Rota PA, Bellini WJ, Anderson LJ.

J Virol Methods. 2005 Sep;128(1-2):21-8.

PMID:
15885812
Items per page

Supplemental Content

Write to the Help Desk